VTGN vs. ANNX, CRVS, TRVI, CMPS, AQST, GOSS, CADL, ATYR, IMMP, and OLMA
Should you be buying Vistagen Therapeutics stock or one of its competitors? The main competitors of Vistagen Therapeutics include Annexon (ANNX), Corvus Pharmaceuticals (CRVS), Trevi Therapeutics (TRVI), COMPASS Pathways (CMPS), Aquestive Therapeutics (AQST), Gossamer Bio (GOSS), Candel Therapeutics (CADL), Atyr PHARMA (ATYR), Immutep (IMMP), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical products" industry.
Vistagen Therapeutics vs.
Vistagen Therapeutics (NASDAQ:VTGN) and Annexon (NASDAQ:ANNX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, community ranking, dividends, risk, earnings, media sentiment and valuation.
Vistagen Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Annexon has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500.
Annexon has a net margin of 0.00% compared to Vistagen Therapeutics' net margin of -6,777.08%. Annexon's return on equity of -38.99% beat Vistagen Therapeutics' return on equity.
In the previous week, Annexon had 14 more articles in the media than Vistagen Therapeutics. MarketBeat recorded 16 mentions for Annexon and 2 mentions for Vistagen Therapeutics. Annexon's average media sentiment score of 0.42 beat Vistagen Therapeutics' score of 0.01 indicating that Annexon is being referred to more favorably in the news media.
78.4% of Vistagen Therapeutics shares are held by institutional investors. 1.3% of Vistagen Therapeutics shares are held by company insiders. Comparatively, 12.7% of Annexon shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Vistagen Therapeutics has higher revenue and earnings than Annexon. Annexon is trading at a lower price-to-earnings ratio than Vistagen Therapeutics, indicating that it is currently the more affordable of the two stocks.
Annexon has a consensus price target of $15.80, indicating a potential upside of 462.28%. Given Annexon's higher possible upside, analysts plainly believe Annexon is more favorable than Vistagen Therapeutics.
Vistagen Therapeutics received 228 more outperform votes than Annexon when rated by MarketBeat users. However, 77.14% of users gave Annexon an outperform vote while only 72.31% of users gave Vistagen Therapeutics an outperform vote.
Summary
Annexon beats Vistagen Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Vistagen Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vistagen Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VTGN) was last updated on 2/22/2025 by MarketBeat.com Staff
Free VTGN Stock Alerts